Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 590-598

  Paeshuyse, Jan ^a   Dallmeier, Kai ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERFERON STIMULATED GENE FACTOR 3; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; TELAPREVIR; TRANSCRIPTION FACTOR;

ANTIVIRAL ACTIVITY; ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; HEPATITIS C; HUMAN; INNATE IMMUNITY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PURINE METABOLISM;

EID: 82955163230     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.030     Document Type: Review

References (88)

1. J.T. Witkowsk, L.N. Simon, R.W. Sidwell, and R.K. Robins Design, synthesis, and broad-spectrum antiviral activity of 1-beta-dribofuranosyl-1,2,4- triazole-3-carboxamide and related nucleosides J. Med. Chem. 15 1972 1150
2. R.W. Sidwell, J.T. Witkowsk, L.B. Allen, R.K. Robins, G.P. Khare, and J.H. Huffman Broad-spectrum antiviral activity of virazole-1-beta-d- ribofuranosyl-1,2,4-triazole-3-carboxamide Science 177 1972 705
3. K.L.B. Borden, and B. Culjkovic-Kraljacic Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk. Lymph. 51 2010 1805 1815
4. P.G. Canonico, M.D. Kastello, C.T. Spears, J.R. Brown, E.A. Jackson, and D.E. Jenkins Effects of ribavirin on red-blood-cells Toxicol. Appl. Pharmacol. 74 1984 155 162
5. P.G. Canonico, M.D. Kastello, T.M. Cosgriff, J.C. Donovan, P.E. Ross, C.T. Spears, and E.L. Stephen Hematological and bone-marrow effects of ribavirin in rhesus-monkeys Toxicol. Appl. Pharmacol. 74 1984 163 172 (Pubitemid 14083682)
6. J.B. Mccormick, I.J. King, P.A. Webb, C.L. Scribner, R.B. Craven, K.M. Johnson, L.H. Elliott, and R. Belmontwilliams Lassa fever - effective therapy with ribavirin N. Engl. J. Med. 314 1986 20 26 (Pubitemid 16183064)
7. S. Brillanti, M. Foli, C. Masci, and M. Miglioli Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: evidence for long-term efficacy and safety Hepatology 24 1996 1074
8. L. Chemello, L. Cavalletto, E. Bernardinello, M. Guido, P. Pontisso, and A. Alberti The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C J. Hepatol. 23 1995 8 12 (Pubitemid 26048737)
9. R. Schvarcz, Z.B. Yun, A. Sonnerborg, and O. Weiland Combined treatment with interferon-alpha-2B and ribavirin for chronic hepatitis-C in patients with a previous nonresponse or nonsustained response to interferon alone J. Med. Virol. 46 1995 43 47
10. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 339 1998 1485 1492 (Pubitemid 28543496)
11. G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, M.L. Shiffman, S. Zeuzem, A. Craxi, M.H. Ling, and J. Albrecht Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N. Engl. J. Med. 339 1998 1493 1499 (Pubitemid 28543497)
12. J.H. Hoofnagle, D. Lau, H. Conjeevaram, D. Kleiner, and A.M. DiBisceglie Prolonged therapy of chronic hepatitis C with ribavirin J. Viral Hepatitis 3 1996 247 252 (Pubitemid 126733924)
13. J. Brok, L.L. Gluud, and C. Gluud Ribavirin monotherapy for chronic hepatitis C Cochrane Database Syst. Rev. 2009
14. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M.H. Ling, and J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
15. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales, D. Haussinger, M. Diago, G. Carosi, and D. Dhumeaux Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975 982
16. L. Delang, L. Coelmont, and J. Neyts Antiviral therapy for hepatitis C virus: beyond the standard of care Viruses-Basel 2 2010 826 866
17. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, and N. Boparai Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1195 1206
18. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, and F. Poordad Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1207 1217
19. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, N. Boparai, and V. Sniukiene Boceprevir (Boc) combined with peginterferon alfa-2B/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (Hcv) genotype (G) 1: sprint-2 final results Hepatology 52 2010 LB-4
20. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, N. Boparai, M. Burroughs, and C.A. Brass Hcv respond-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus pegintron (peginterferon alfa-2B)/ribavirin Hepatology 52 2010 216
21. T. Burney, and G. Dusheiko Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients Expert Rev. Anti-Infect. Ther. 9 2011 151 160
22. P. Marcellin, X. Forns, T. Goeser, P. Ferenci, F. Nevens, G. Carosi, J.P. Drenth, L. Serfaty, K. De Backer, and R. Van Heeswijk Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C Gastroenterology 140 2011 459-U159
23. W.P. Hofmann, and S. Zeuzem A new standard of care for the treatment of chronic HCV infection Nat. Rev. Gastroenterol. Hepatol. 8 2011 257 264
24. I. Vliegen, J. Paeshuyse, I.H. Shih, G. Purstinger, S. Bondy, W.A. Lee, W.D. Zhong, and J. Neyts In vitro combination therapy with tegobuvir (GS-9190) is highly efficient in curing cells from HCV replicon and in delaying/preventing the development of antiviral resistance Antiviral Res. 90 2011 145
25. L. Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, and G. Vuagniaux DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS ONE 2010 5
26. L. Coelmont, P. Gallay, M. Bobardt, S. Kaptein, J. Paeshuyse, I. Vliegen, G. Vuagniaux, and J. Neyts Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor Debio 025 J. Hepatol. 50 2009 88
27. L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J.M. Dumont, G. Vuagniaux, and J. Neyts Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrobial Agents Chemother. 53 2009 967 976
28. J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
29. Q.N. Shu, and V. Nair Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery Med. Res. Rev. 28 2008 219 232 (Pubitemid 351281187)
30. P. Leyssen, E. De Clercq, and J. Neyts The anti-yellow fever virus activity of ribavirin is independent of error-prone replication Mol. Pharmacol. 69 2006 1461 1467
31. P. Leyssen, J. Balzarini, E. De Clercq, and J. Neyts The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase J. Virol. 79 2005 1943 1947 (Pubitemid 40459141)
32. K. Mori, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, and N. Kato Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system Virus Res. 157 2011 61 70
33. S.F. Zhou, R. Liu, B.M. Baroudy, B.A. Malcolm, and G.R. Reyes The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA Virology 310 2003 333 342 (Pubitemid 37492916)
34. M. Cornberg, H. Hinrichsen, G. Teuber, T. Berg, U. Naumann, C. Falkenberg, S. Zeuzem, and M.P. Manns Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C J. Hepatol. 37 2002 843 847 (Pubitemid 35404225)
35. J.G. McHutchison, M.L. Shiffman, R.C. Cheung, S.C. Gordon, T.L. Wright, J.C. Pottage, L. McNair, E. Ette, S. Moseley, and J. Alam A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C Antiviral Ther. 10 2005 635 643 (Pubitemid 41224955)
36. P. Marcellin, Y. Horsmans, F. Nevens, J.D. Grange, J.P. Bronowicki, D. Vetter, R. Kauffman, S. Knox, L. McNair, S. Moseley, and J. Alam A phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin J. Hepatol. 40 2004 492
37. J.D. Graci, and C.E. Cameron Mechanisms of action of ribavirin against distinct viruses Rev. Med. Virol. 16 2006 37 48 (Pubitemid 43133592)
38. R.T. Chung, M. Gale Jr., S.J. Polyak, S.M. Lemon, T.J. Liang, and J.H. Hoofnagle Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop Hepatology 47 2008 306 320 (Pubitemid 351171068)
39. J.A. Heck, A.M.I. Lam, N. Narayanan, and D.N. Frick Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes Antimicrobial Agents Chemother. 52 2008 1901 1911 (Pubitemid 351758521)
40. B. Rehermann Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J. Clin. Investig. 119 2009 1745 1754
41. W.P. Hofmann, E. Herrmann, C. Sarrazin, and S. Zeuzem Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms Liver Int. 28 2008 1332 1343
42. E. Barnes, H.C. Gelderblom, I. Humphreys, N. Semmo, H.W. Reesink, M.G.H.M. Beld, R.A.W. van Lier, and P. Klenerman Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection J. Infect. Dis. 199 2009 819 828
43. T. Fujimoto, M. Tomimatsu, D. Iga, H. Endo, and K. Otsuka Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C J. Gastroenterol. Hepatol. 23 2008 E432 E437
44. S.Y. Liu, D.J. Sanchez, and G.H. Cheng New developments in the induction and antiviral effectors of type I interferon Curr. Opin. Immunol. 23 2011 57 64
45. L.M. Chen, I. Borozan, J. Feld, J. Sun, L.L. Tannis, C. Coltescu, J. Heathcote, A.M. Edwards, and I.D. McGilvray Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 2005 1437 1444 (Pubitemid 40712193)
46. T. Asselah, I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, M.P. Ripault, N. Boyer, M. Martinot-Peignoux, D. Valla, M. Vidaud, and P. Marcellin Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut 57 2008 516 523 (Pubitemid 351442537)
47. J.J. Feld, S. Nanda, Y. Huang, W.P. Chen, M. Cam, S.N. Pusek, L.M. Schweigler, D. Theodore, S.L. Zacks, T.J. Liang, and M.W. Fried Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response Hepatology 46 2007 1548 1563 (Pubitemid 350155537)
48. J.J. Feld, G.A. Lutchman, T. Heller, K. Hara, J.K. Pfeiffer, R.D. Leff, C. Meek, M. Rivera, M. Ko, and C. Koh Ribavirin improves early responses to peginterferon through improved interferon signaling Gastroenterology 139 2010 154 239
49. E. Thomas, J.J. Feld, Q.S. Li, Z.Y. Hu, M.W. Fried, and T.J. Liang Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models Hepatology 53 2011 32 41
50. M.S. Sixtos-Alonso, F. Sanchez-Munoz, J.F. Sanchez-Avila, R.A. Martinez, A.D. Lopez, F.V. Vorackova, and M. Uribe IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFN alpha 2b and ribavirin in patients with hepatitis C virus genotype 1 Arch. Med. Res. 42 2011 28 33
51. L.M. Chen, J. Sun, L. Meng, J. Heathcote, A.M. Edwards, and I.D. McGilvray ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment J. Gen. Virol. 91 2010 382 388
52. L.M. Chen, I. Borozan, J. Sun, M. Guindi, S. Fischer, J. Feld, N. Anand, J. Heathcote, A.M. Edwards, and I.D. McGilvray Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection Gastroenterology 138 2010 1123 1415
53. J. Lee, C.C.N. Wu, K.J. Lee, T.H. Chuang, K. Katakura, Y.T. Liu, M. Chan, R. Tawatao, M. Chung, and C. Shen Activation of anti-hepatitis C virus responses via Toll-like receptor 7 Proc. Natl. Acad. Sci. U. S. A. 103 2006 1828 1833 (Pubitemid 43228778)
54. A. Kentsis, I. Topisirovic, B. Culjkovic, L. Shao, and K.L.B. Borden Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap Proc. Natl. Acad. Sci. U. S. A. 101 2004 18105 18110 (Pubitemid 40054081)
55. A.B. Rosenfeld, and V.R. Racaniello Hepatitis C virus internal ribosome entry site-dependent translation in Saccharomyces cerevisiae is independent of polypyrimidine tract-binding protein, poly(rC)-binding protein 2, and La protein J. Virol. 79 2005 10126 10137 (Pubitemid 41098553)
56. P. Mannova, and L. Beretta Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication J. Virol. 79 2005 8742 8749 (Pubitemid 40934785)
57. K. Tan, B. Culjkovic, A. Amri, and K.L.B. Borden Ribavirin targets eIF4E dependent Akt survival signaling Biochem. Biophys. Res. Commun. 375 2008 341 345
58. Y.P. He, S.L. Tan, S.U. Tareen, S. Vijaysri, J.O. Langland, B.L. Jacobs, and M.G. Katze Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A J. Virol. 75 2001 5090 5098 (Pubitemid 32448531)
59. G.C. Scheper, B. van Kollenburg, J.Z. Hu, Y.J. Luo, D.J. Goss, and C.G. Proud Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA J. Biol. Chem. 277 2002 3303 3309 (Pubitemid 34953196)
60. L. Furic, L.W. Rong, O. Larsson, I.H. Koumakpayi, K. Yoshida, A. Brueschke, E. Petroulakis, N. Robichaud, M. Pollak, and L.A. Gaboury eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression Proc. Natl. Acad. Sci. U. S. A. 107 2010 14134 14139
61. A. Meshkini, R. Yazdanparast, and K. Nouri Intracellular GTP level determines cell's fate toward differentiation and apoptosis Toxicol. Appl. Pharmacol. 253 2011 188 196
62. D.L. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, and A.J. Muir Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
63. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, and S. Hige Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet. 41 2009 1105 1111
64. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, and E. Powell IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 2009 1100
65. M. Lindh, M. Lagging, M. Farkkila, N. Langeland, K. Morch, S. Nilsson, G. Norkrans, C. Pedersen, and M.R. Buhl Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus J. Infect. Dis. 203 2011 1748 1752
66. M. Honda, A. Sakai, T. Yamashita, Y. Nakamoto, E. Mizukoshi, Y. Sakai, T. Yamashita, M. Nakamura, T. Shirasaki, and K. Horimoto Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
67. P. Proost, A.K. Vynckier, F. Mahieu, W. Put, B. Grillet, S. Struyf, A. Wuyts, G. Opdenakker, and J. Van Damme Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis Eur. J. Immunol. 33 2003 3146 3153 (Pubitemid 37428347)
68. G. Askarieh, A. Alsio, P. Pugnale, F. Negro, C. Ferrari, A.U. Neumann, J.M. Pawlotsky, S.W. Schalm, S. Zeuzem, and G. Norkrans Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C Hepatology 51 2010 1523 1530
69. A. Casrouge, J. Decalf, M. Ahloulay, C. Lababidi, H. Mansour, A. Vallet-Pichard, V. Mallet, E. Mottez, J. Mapes, and A. Fontanet Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV J. Clin. Investig. 121 2011 308 317
70. J. Morello, L. Cuenca, V. Soriano, J. Medrano, A. Madejon, E. Vispo, P. Barreiro, P. Labarga, I. Jimenez-Nacher, and S. Rodriguez-Novoa Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection J. Infect. Dis. 202 2010 1185 1191
71. M. Lagging, G. Askarieh, F. Negro, S. Bibert, J. Soderholm, J. Westin, M. Lindh, A. Romero, G. Missale, and C. Ferrari Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms PLoS ONE 6 2011 e17232
72. N.R. Shah, A. Sunderland, and V.Z. Grdzelishvili Cell type mediated resistance of vesicular stomatitis virus and sendai virus to ribavirin PLoS ONE 2010 5
73. K.D. Ibarra, and J.K. Pfeiffer Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance J. Virol. 83 2009 4538 4547
74. K.D. Ibarra, M.K. Jain, and J.K. Pfeiffer Host-based ribavirin resistance influences hepatitis C virus replication and treatment response J. Virol. 85 2011 7273 7283
75. A.W. Murray Biological significance of purine salvage Annu. Rev. Biochem. 40 1971 811
76. Y. Hitomi, E.T. Cirulli, J. Fellay, J.G. McHutchison, A.J. Thompson, C.E. Gumbs, K.V. Shianna, T.J. Urban, and D.B. Goldstein Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function Gastroenterology 140 2011 1314 1321
77. J. Fellay, A.J. Thompson, D.L. Ge, C.E. Gumbs, T.J. Urban, K.V. Shianna, L.D. Little, P. Qiu, A.H. Bertelsen, and M. Watson ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
78. A.J. Thompson, J. Fellay, K. Patel, H.L. Tillmann, S. Naggie, D.L. Ge, T.J. Urban, K.V. Shianna, A.J. Muir, and M.W. Fried Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139 2010 1181
79. H. Ochi, T. Maekawa, H. Abe, Y. Hayashida, R. Nakano, M. Kubo, T. Tsunoda, C.N. Hayes, H. Kumada, Y. Nakamura, and K. Chayama ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients Gastroenterology 139 2010 1190
80. E. Domingo, and S. Wain-Hobson The 30th anniversary of quasispecies meeting on 'Quasispecies: past, present and future' Embo Rep. 10 2009 444 448
81. S.C. Manrubia, E. Domingo, and E. Lazaro Pathways to extinction: beyond the error threshold Philos. Trans. R. Soc. B: Biol. Sci. 365 2010 1943 1952
82. N.M. Dixit, and A.S. Perelson The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus Cell Mol. Life Sci. 63 2006 832 842 (Pubitemid 43724073)
83. F. Cao, M.J. Donlin, K. Turner, X. Cheng, and J.E. Tavis Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon alpha plus ribavirin therapy J. Viral Hepatitis 18 2011 349 357
84. K.C. Young, K.L. Lindsay, K.J. Lee, W.C. Liu, J.W. He, S.L. Milstein, and M.M.C. Lai Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy Hepatology 38 2003 869 878 (Pubitemid 37221670)
85. S.S. Hmwe, H. Aizaki, T. Date, K. Murakami, K. Ishii, T. Miyamura, K. Koike, T. Wakita, and T. Suzuki Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin Antiviral Res. 85 2010 520 524
86. M. Nakamura, H. Saito, M. Ikeda, S. Tada, N. Kumagai, N. Kato, K. Shimotohno, and T. Hibi Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment J. Med. Virol. 80 2008 632 639 (Pubitemid 351358561)
87. C.L. Ward, A. Dev, S. Rigby, W.T. Symonds, K. Patel, A. Zekry, J.M. Pawlotsky, and J.G. McHutchison Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase J. Viral Hepatitis 15 2008 571 577
88. J.K. Pfeiffer, and Kirkegaard K Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA J. Virol. 79 2005 2346 2355 (Pubitemid 40204589)